5 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $22000 | -$61M | 0.0% | -312631.8% | -$44M | — | $16M |
| 2024 | $0 | -$53M | — | — | -$41M | — | $48M |
| 2023 | $2M | -$71M | 0.0% | -4687.9% | -$64M | — | $36M |
| 2022 | $3M | -$58M | 0.0% | -1889.3% | -$76M | — | $58M |
| 2021 | $2M | -$4M | 0.0% | -168.7% | -$7M | — | $56M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $16000 | -$4M | 0.0% | -28850.0% | — | — | $9M |
| Dec '25 | — | -$14M | — | — | -$7M | — | $16M |
| Sep '25 | — | -$18M | — | — | -$9M | — | $12M |
| Jun '25 | — | -$15M | — | — | -$13M | — | $22M |
| Mar '25 | $0 | -$14M | — | — | -$14M | — | $34M |
| Dec '24 | $0 | -$610000 | — | — | -$14M | — | $48M |
| Sep '24 | $0 | -$29M | — | — | -$8M | — | $10M |
| Jun '24 | $0 | -$11M | — | — | -$8M | — | $16M |
| Mar '24 | $0 | -$12M | — | — | -$12M | — | $24M |
| Dec '23 | $0 | -$19M | — | — | -$7M | — | $36M |
| Sep '23 | $255000 | -$15M | 0.0% | -17206.3% | -$17M | — | $39M |
| Jun '23 | $687000 | -$19M | 0.0% | -2210.8% | -$17M | — | $37M |
| Mar '23 | $1M | -$19M | 0.0% | -1444.4% | -$23M | — | $32M |
| Dec '22 | -$191000 | -$58M | 0.0% | 8792.7% | -$18M | — | $58M |
| Sep '22 | $2M | -$17M | 0.0% | -972.8% | -$24M | — | $115M |
| Jun '22 | $1M | -$12M | 0.0% | -1964.9% | -$17M | — | $140M |
| Mar '22 | $854000 | -$12M | 0.0% | -1376.8% | -$17M | — | $38M |
| Dec '21 | $543000 | -$3M | 0.0% | -619.3% | -$16M | — | $56M |
| Sep '21 | $926000 | -$291680 | 0.0% | -31.8% | -$10M | — | $74M |
| Jun '21 | $778000 | -$207244 | 0.0% | -26.8% | — | — | $83M |
How the market has priced SNTI against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 4 years, Senti Biosciences Holdings, Inc.'s revenue has declined 68.7% per year. These are computed facts, not advice.
As of FY2025, Senti Biosciences Holdings, Inc. reported — of total debt against $16M of cash.
In FY2025, gross margin was —, operating margin -312631.8%, and net margin -279263.6%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.